BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23440406)

  • 1. The role of the serum RANKL/OPG ratio in the healing of intertrochanteric fractures in elderly patients.
    Wang XF; Zhang YK; Yu ZS; Zhou JL
    Mol Med Rep; 2013 Apr; 7(4):1169-72. PubMed ID: 23440406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, IL-6 and TNF-alpha in patients with a concomitant head injury and fracture.
    Lee JS; Ryu CH; Moon NH; Kim SJ; Park SY; Suh KT
    Arch Orthop Trauma Surg; 2009 May; 129(5):711-8. PubMed ID: 18427820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in serum levels of TNF-alpha, IL-6, OPG, RANKL and their correlation with radiographic and clinical assessment in fragility fractures and high energy fractures.
    Giganti MG; Liuni F; Celi M; Gasbarra E; Zenobi R; Tresoldi I; Modesti A; Bei R; Tarantino U
    J Biol Regul Homeost Agents; 2012; 26(4):671-80. PubMed ID: 23241117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are OPG and RANKL involved in human fracture healing?
    Köttstorfer J; Thomas A; Gregori M; Kecht M; Kaiser G; Eipeldauer S; Sarahrudi K
    J Orthop Res; 2014 Dec; 32(12):1557-61. PubMed ID: 25212894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
    Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
    Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures.
    Abdallah BM; Stilgren LS; Nissen N; Kassem M; Jørgensen HR; Abrahamsen B
    Calcif Tissue Int; 2005 Feb; 76(2):90-7. PubMed ID: 15570403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
    Spelling P; Bonfá E; Caparbo VF; Pereira RM
    Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of osteoprogenitor cells is affected by trauma-haemorrhage.
    Neunaber C; Yesilkaya P; Pütz C; Krettek C; Hildebrand F
    Injury; 2013 Oct; 44(10):1279-84. PubMed ID: 23773407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures.
    Galeone A; Brunetti G; Rotunno C; Oranger A; Colucci S; de Luca Tupputi Schinosa L; Zallone A; Grano M; Paparella D
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):e141-7. PubMed ID: 23671202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
    Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
    Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.
    Polyzos SA; Anastasilakis AD; Efstathiadou Z; Kita M; Litsas I; Avramidis A; Arsos G; Moralidis E; Gerou S; Pavlidou V; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Nov; 41(11):846-50. PubMed ID: 19670154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
    Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
    Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
    Szymczak J; Bohdanowicz-Pawlak A
    Horm Metab Res; 2013 Sep; 45(10):759-64. PubMed ID: 23888411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.